These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34885006)

  • 1. Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results.
    Comandone A; Vana F; Comandone T; Tucci M
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
    Bersanelli M; Iacovelli R; Buti S; Houede N; Laguerre B; Procopio G; Lheureux S; Fischer R; Negrier S; Ravaud A; Oudard S; Escudier B; Albiges L; Porta C
    Eur Urol Oncol; 2021 Apr; 4(2):274-281. PubMed ID: 31331862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma].
    Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend JE; Ivanyi P; Keilholz U; Kuczyk MA
    Aktuelle Urol; 2020 Dec; 51(6):572-581. PubMed ID: 33027832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current management of metastatic renal cell carcinoma: evolving new therapies.
    Kumar R; Kapoor A
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):231-237. PubMed ID: 28590313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment options for metastatic renal cell carcinoma.
    Rodriguez-Vida A; Hutson TE; Bellmunt J; Strijbos MH
    ESMO Open; 2017; 2(2):e000185. PubMed ID: 28761748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.
    D'Aniello C; Berretta M; Cavaliere C; Rossetti S; Facchini BA; Iovane G; Mollo G; Capasso M; Pepa CD; Pesce L; D'Errico D; Buonerba C; Di Lorenzo G; Pisconti S; De Vita F; Facchini G
    Front Oncol; 2019; 9():1400. PubMed ID: 31921657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
    Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
    Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
    Ito K
    Int J Urol; 2019 Sep; 26(9):868-877. PubMed ID: 31183903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
    Gill DM; Agarwal N; Vaishampayan U
    Am Soc Clin Oncol Educ Book; 2017; 37():319-329. PubMed ID: 28561652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
    Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
    J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells-A View towards Second Line Renal Cell Carcinoma Treatment.
    Juengel E; Schnalke P; Rutz J; Maxeiner S; Chun FK; Blaheta RA
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.